Press Releases Carisma Therapeutics, Inc.

Equities

CARM

US14216R1014

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
1.67 ^USD	+1.83%		-1.76%	-43.00%

Apr. 11	BTIG Starts Carisma Therapeutics With Buy Rating, $6 Price Target	MT
Apr. 02	HC Wainwright Adjusts Price Target on Carisma Therapeutics to $9 From $11, Maintains Buy Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Carisma Therapeutics to Present New Data at the American Society of Gene and Cell Therapy Annual Meeting	Apr. 23	AQ
Carisma Therapeutics to Present at Upcoming Conferences	Apr. 03	PR
Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	Apr. 02	AQ
Carisma Therapeutics Announces Changes to its Board of Directors	Apr. 01	PR
Carisma Therapeutics to Participate in TD Cowen's 44th Annual Health Care Conference	Feb. 28	PR
Carisma Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference	Dec. 21	PR
Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte	Nov. 28	PR
Carisma Therapeutics to Participate in Evercore ISI HealthCONx Conference	Nov. 22	PR
Carisma Presents Pre-Clinical Proof of Concept for in vivo CAR-M using mRNA platform in collaboration with Moderna at SITC	Nov. 01	AQ
Carisma to Present First Results From in vivo CAR-M Collaboration with Moderna at SITC 2023	23-10-26	AQ
Carisma Therapeutics to Present at Upcoming Investor Conferences	23-09-05	PR
Carisma Announces Latest Data from Phase 1 Clinical Trial of CT-0508 at 8th Annual CAR-TCR Summit	23-09-04	AQ
Carisma Therapeutics : Corporate Presentation	23-09-01	PU
Carisma Announces Latest Data from Phase 1 Clinical Trial of CT-0508 at 8th Annual CAR-TCR Summit	23-09-01	PR
Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in September 2023	23-08-24	PR
Carisma Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights	23-08-10	PR
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Study of CT-0508 in Combination with KEYTRUDA in Patients with HER2 Overexpressing Solid Tumors	23-06-29	AQ
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Study of CT-0508 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HER2 Overexpressing Solid Tumors	23-06-28	PR
Carisma Therapeutics to be Added to Russell 2000®, Russell 3000® and Russell Microcap® Indexes	23-06-26	PR
Carisma Therapeutics : Corporate Presentation	23-06-14	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Carisma Therapeutics, Inc.

Equities

CARM

US14216R1014

Press Releases

Filters